Your browser is no longer supported. Please, upgrade your browser.
Settings
PRVB [NASD]
Provention Bio, Inc.
Index- P/E- EPS (ttm)-2.11 Insider Own19.02% Shs Outstand63.38M Perf Week0.97%
Market Cap396.12M Forward P/E- EPS next Y-1.95 Insider Trans0.00% Shs Float52.37M Perf Month-6.16%
Income-125.50M PEG- EPS next Q-0.51 Inst Own37.40% Short Float5.31% Perf Quarter3.48%
Sales- P/S- EPS this Y-76.90% Inst Trans-0.16% Short Ratio5.55 Perf Half Y-19.04%
Book/sh2.49 P/B2.51 EPS next Y8.50% ROA-74.10% Target Price15.64 Perf Year-50.40%
Cash/sh2.78 P/C2.25 EPS next 5Y- ROE-85.30% 52W Range5.59 - 20.05 Perf YTD-63.11%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-68.83% Beta-
Dividend %- Quick Ratio7.30 Sales past 5Y- Gross Margin- 52W Low11.81% ATR0.22
Employees59 Current Ratio7.30 Sales Q/Q- Oper. Margin- RSI (14)48.42 Volatility2.75% 3.64%
OptionableYes Debt/Eq0.00 EPS Q/Q-2.30% Profit Margin- Rel Volume0.68 Prev Close6.18
ShortableYes LT Debt/Eq0.00 EarningsAug 05 BMO Payout- Avg Volume501.96K Price6.25
Recom2.00 SMA200.15% SMA50-1.82% SMA200-30.29% Volume340,648 Change1.13%
Apr-09-21Reiterated SVB Leerink Outperform $26 → $16
Apr-09-21Downgrade RBC Capital Mkts Outperform → Sector Perform $27 → $25
Jun-16-20Reiterated H.C. Wainwright Buy $20 → $26
Jun-04-20Initiated RBC Capital Mkts Outperform $25
Jun-04-20Initiated Oppenheimer Outperform $29
Jan-24-20Initiated Cantor Fitzgerald Overweight $25
Jun-26-19Reiterated H.C. Wainwright Buy $8 → $20
Jun-10-19Initiated Chardan Capital Markets Buy $20
Feb-22-19Initiated SVB Leerink Outperform $6
Oct-26-21 01:43PM  
07:30AM  
Oct-21-21 09:32PM  
Sep-23-21 07:30AM  
Sep-16-21 07:30AM  
Sep-13-21 07:30AM  
Sep-10-21 12:19PM  
Aug-30-21 10:34AM  
Aug-09-21 08:37PM  
Aug-06-21 07:00PM  
02:04PM  
Aug-05-21 08:45AM  
07:00AM  
Jul-29-21 07:00AM  
Jul-20-21 02:20PM  
01:35PM  
10:40AM  
10:03AM  
09:36AM  
Jul-19-21 03:51PM  
03:00PM  
02:30PM  
12:21PM  
10:40AM  
10:15AM  
10:00AM  
10:00AM  
09:00AM  
05:40AM  
12:50AM  
Jul-18-21 11:49AM  
09:30AM  
09:00AM  
Jul-16-21 07:30PM  
03:53PM  
02:10PM  
01:05PM  
11:35AM  
11:25AM  
10:35AM  
10:11AM  
06:52AM  
Jul-15-21 07:37PM  
06:05PM  
04:01PM  
02:30PM  
12:30PM  
12:00PM  
11:00AM  
10:30AM  
10:03AM  
05:40AM  
12:50AM  
Jul-14-21 09:00PM  
06:34PM  
05:09PM  
02:30PM  
01:00PM  
09:30AM  
09:00AM  
05:40AM  
01:30AM  
Jul-13-21 08:15PM  
07:45PM  
01:40PM  
01:00PM  
11:45AM  
11:00AM  
05:40AM  
12:20AM  
Jul-12-21 06:54PM  
04:51PM  
01:00PM  
01:00PM  
11:30AM  
08:48AM  
07:00AM  
05:40AM  
Jul-11-21 11:55PM  
10:30AM  
Jul-10-21 06:46AM  
Jul-09-21 06:23PM  
04:59PM  
04:51PM  
03:33PM  
02:00PM  
Jul-08-21 12:00PM  
11:00AM  
10:00AM  
05:30AM  
Jul-07-21 11:00PM  
09:10PM  
08:22PM  
03:58PM  
02:30PM  
12:58PM  
11:30AM  
11:15AM  
10:10AM  
Jul-06-21 04:49PM  
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, an oral CSF-1R inhibitor, which has completed Phase IIa clinical trial for the treatment of Crohn's disease; PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. The company was incorporated in 2016 and is headquartered in Red Bank, New Jersey.